Drugs / Atebimetinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07562152 | Jun 2026 → Jun 2028 expected | pancreatic ductal adenocarcinoma | Immuneering Corporation | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-10-02 | Immuneering Corporation | Results Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) immuneering.com ↗
These findings support Immuneering’s plans to conduct a Phase 2 study of atebimetinib in combination with PD-1 blockade in patients with lung cancer. |
| 2026-09-28 | Immuneering Corporation | Results Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer immuneering.com ↗
The findings, presented by Peter Vu, M.D., MHA, UC San Diego Health, support a potential dual mechanism of action through which atebimetinib may improve survival in pancreatic cancer by both reducing tumor volume and preserving body mass. |
| 2026-07-21 | Immuneering Corporation | Results Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition immuneering.com ↗
In head-to-head in vivo studies, atebimetinib produced deeper, more durable tumor growth inhibition than the FDA-approved MEK inhibitor binimetinib |
| 2026-06-01 | Immuneering Corporation | Results Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO immuneering.com ↗
The presentation showcases data from an expanded cohort totaling 55 first-line pancreatic cancer patients. |
| 2026-05-21 | Immuneering Corporation | Results Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy immuneering.com ↗
Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported a 17.3-month median overall survival (OS) in first-line metastatic pancreatic cancer patients treated in its Phase 2a clinical trial evaluating atebimetinib (IMM-1-104) plus modified gemcitabine/nab-paclitaxel (mGnP), as of the April 24, 2026 data cutoff date. |
| 2026-04-20 | Immuneering Corporation | Results Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond immuneering.com ↗
Today’s data at AACR add genetic rationale to support atebimetinib’s observed durable tumor shrinkage and its optimal use in the first-line setting by showing that the most common RAS-inhibitor resistance mechanisms are rarely seen in atebimetinib-treated patients. |
| 2026-03-17 | Immuneering Corporation | Results Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival immuneering.com ↗
Immuneering will present an analysis of circulating tumor DNA (ctDNA) from ≥64 patients with RAS-mutant solid tumors treated with atebimetinib, showing that acquired MAPK pathway alterations are rarely seen in patients treated with atebimetinib. |
| 2026-01-07 | Immuneering Corporation | Results Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP immuneering.com ↗
Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced positive updated overall survival (OS) and safety data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients (N=34), with over 13 months median follow up time. |
All press releases naming this drug 11 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atebimetinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07562152 ↗ |